<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01214317</url>
  </required_header>
  <id_info>
    <org_study_id>389050</org_study_id>
    <nct_id>NCT01214317</nct_id>
  </id_info>
  <brief_title>Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple Sclerosis</brief_title>
  <acronym>IMPAMS</acronym>
  <official_title>Study of Combinative Effect of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Patients With Aggressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isfahan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isfahan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of combinative induction therapy with
      mitoxantrone and plasmapheresis versus induction therapy with mitoxantrone alone in cases of
      aggressive multiple sclerosis
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">February 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>expanded disability status score</measure>
    <time_frame>At the end of month 8 after treatment initiation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of MS plaques in brain MRI</measure>
    <time_frame>month 8 after treatment initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>annual relapse rate</measure>
    <time_frame>month 17 after treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of MS plaques in brain MRI</measure>
    <time_frame>month 17 after treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>expanded disability status score</measure>
    <time_frame>month 17 after treatment initiation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>mitoxantrone and plasmapheresis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>mitoxantrone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>plasmapheresis</intervention_name>
    <description>3 courses of plasmapheresis are performed before mitoxantrone injection in first 3 months to investigate the efficacy of plasmapheresis in comparison with the other arm that are only treated with mitoxantrone</description>
    <arm_group_label>mitoxantrone and plasmapheresis</arm_group_label>
    <other_name>novantrone</other_name>
    <other_name>plasma exchange</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aggressive multiple sclerosis in attack phase

          -  EDSS: 1-5

          -  No contraindication for mitoxantrone prescription

          -  No past history of mitoxantrone injection

          -  No history of corticosteroid and immunosuppressive therapy in last 3 months

        Exclusion Criteria:

          -  Patient's incompliance

          -  Severe drug induced side effects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masoud Etemadifar</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alzahra Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alahra hospital</name>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2010</study_first_submitted>
  <study_first_submitted_qc>October 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2010</study_first_posted>
  <last_update_submitted>August 16, 2011</last_update_submitted>
  <last_update_submitted_qc>August 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Masoud Etemadifar</name_title>
    <organization>Isfahan university of medical sciences</organization>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>mitoxantrone</keyword>
  <keyword>plasmapheresis</keyword>
  <keyword>induction therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

